Induction of a long-lasting antitumor immunity by a trifunctional bispecific antibody
- PMID: 11588051
- DOI: 10.1182/blood.v98.8.2526
Induction of a long-lasting antitumor immunity by a trifunctional bispecific antibody
Abstract
Bispecific antibodies (bsAbs) can efficiently mediate tumor cell killing by redirecting preactivated or costimulated T cells to disseminated tumor cells, especially in a minimal residual disease situation. This study demonstrates that the trifunctional bsAb BiLu is able to kill tumor cells very efficiently without any additional costimulation of effector cells in vitro and in vivo. Remarkably, this bsAb also induces a long-lasting protective immunity against the targeted syngeneic mouse tumors (B16 melanoma and A20 B-cell lymphoma, respectively). A strong correlation was observed between the induction of a humoral immune response with tumor-reactive antibodies and the survival of mice. This humoral response was at least in part tumor specific as shown in the A20 model by the detection of induced anti-idiotype antibodies. Both the survival of mice and antitumor titers were significantly diminished when F(ab')(2) fragments of the same bsAb were applied, demonstrating the importance of the Fc region in this process. With the use of T-cell depletion, a contribution of a cellular antitumor response could be demonstrated. These results reveal the necessity of the Fc region of the bsAb with its potent immunoglobulin subclass combination mouse immunoglobulin G2a (IgG2a) and rat IgG2b. The antigen-presenting system seems to be crucial for achieving an efficient tumor cell killing and induction of long-lasting antitumor immunity. Hereby, the recruitment and activation of accessory cells by the intact bsAb is essential.
Similar articles
-
Trifunctional bispecific antibodies induce tumor-specific T cells and elicit a vaccination effect.Cancer Res. 2012 Aug 15;72(16):3958-66. doi: 10.1158/0008-5472.CAN-12-0146. Epub 2012 Jun 28. Cancer Res. 2012. PMID: 22745368
-
Inhibition of bispecific monoclonal antibody (bsAb)-targeted cytolysis by human anti-mouse antibodies in ovarian carcinoma patients treated with bsAb-targeted activated T-lymphocytes.Int J Cancer. 1995 Feb 8;60(4):450-7. doi: 10.1002/ijc.2910600405. Int J Cancer. 1995. PMID: 7829257 Clinical Trial.
-
Cancer vaccines compensate for the insufficient induction of protective tumor-specific immunity of CD3 bispecific antibody therapy.J Immunother Cancer. 2025 Jan 11;13(1):e010331. doi: 10.1136/jitc-2024-010331. J Immunother Cancer. 2025. PMID: 39800374 Free PMC article.
-
Bispecific antibodies and trispecific immunocytokines for targeting the immune system against cancer: preparing for the future.BioDrugs. 2013 Feb;27(1):35-53. doi: 10.1007/s40259-012-0008-z. BioDrugs. 2013. PMID: 23329400 Review.
-
Toward the production of bispecific antibody fragments for clinical applications.J Hematother. 1995 Oct;4(5):463-70. doi: 10.1089/scd.1.1995.4.463. J Hematother. 1995. PMID: 8581386 Review.
Cited by
-
Epothilone B enhances surface EpCAM expression in ovarian cancer Hey cells.Gynecol Oncol. 2010 Nov;119(2):345-50. doi: 10.1016/j.ygyno.2010.07.005. Epub 2010 Aug 2. Gynecol Oncol. 2010. PMID: 20674962 Free PMC article.
-
Systemic effect of catumaxomab in a patient with metastasized colorectal cancer: a case report.BMC Cancer. 2013 Dec 31;13:618. doi: 10.1186/1471-2407-13-618. BMC Cancer. 2013. PMID: 24380380 Free PMC article.
-
Humoral response to catumaxomab correlates with clinical outcome: results of the pivotal phase II/III study in patients with malignant ascites.Int J Cancer. 2012 May 1;130(9):2195-203. doi: 10.1002/ijc.26258. Epub 2011 Sep 27. Int J Cancer. 2012. PMID: 21702044 Free PMC article. Clinical Trial.
-
Re-challenge with catumaxomab in patients with malignant ascites: results from the SECIMAS study.Med Oncol. 2014 Dec;31(12):308. doi: 10.1007/s12032-014-0308-x. Epub 2014 Nov 4. Med Oncol. 2014. PMID: 25367854 Clinical Trial.
-
Symmetry breaking: bispecific antibodies, the beginnings, and 50 years on.Cancer Immun. 2012;12:12. Epub 2012 May 1. Cancer Immun. 2012. PMID: 22896757 Free PMC article. Review. No abstract available.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases